Prevalence and Prognosis of Anemia in Dogs with Degenerative Mitral Valve Disease

Table 2

Clinical test results in 114 dogs with degenerative mitral valvular disease according to the modified New York Heart Association (NYHA) functional classification.

Parameter	NYHA II ()	NYHA III ()	NYHA IV ()
Hb, g/dL	16.9 ± 2.0	14.5 ± 2.8^†	13.8 ± 2.9^†
Packed cell volume, %	47.1 ± 5.5	39.6 ± 8.1^†	37.8 ± 7.9^†
RBC count, 10^6/µL	7.2 ± 1.0	6.1 ± 1.2^†	5.9 ± 1.4^†
Prevalence of anemia	0% (0/38)	15.2% (7/46)	33.3%^† (10/30)
Albumin, g/dL	3.3 ± 0.5	3.1 ± 0.5	3.1 ± 0.4^†
BUN, mg/dL	26.5 ± 15.8	37.3 ± 14.9	50.8 ± 17.8^†
CRE, mg/dL	0.9 ± 0.4	1.1 ± 0.6	1.4 ± 1.0^†
Prevalence of azotemia	34.2% (13/38)	41.3% (19/46)	63.3% (19/30)
Prevalence of CRE > 1.6 mg/dL	5.3% (2/38)	17.4% (8/46)	23.3%^† (7/30)
Urine specific gravity	1.028 ± 0.011	1.025 ± 0.012	1.023 ± 0.009

Data are presented as mean ± SD or % ().
BUN, blood urea nitrogen; CRE, blood creatinine; Hb, hemoglobin; RBC, red blood cell.
^† versus class II.